Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137173 · ClinicalTrials.gov registry record · Phase 3
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
A Phase 3 study of Acute Bacterial Skin and Skin Structure Infections, sponsored by Basilea Pharmaceutica.
- Completed
- Registry status
- Phase 3
- Development phase
- 679
- Enrollment target
- 20
- Study locations
NCT03137173 is a Phase 3 study of Acute Bacterial Skin and Skin Structure Infections that has completed, run by Basilea Pharmaceutica. The registered enrollment target is 679 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT03137173, a Phase 3 study of Acute Bacterial Skin and Skin Structure Infections, has completed, sponsored by Basilea Pharmaceutica.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 679 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Conditions Studied
Interventions
- DRUG ceftobiprole medocaril
- DRUG vancomycin+aztreonam
Study Locations (20)
California
- Physician Alliance Research Center - Anaheim
- Saint Joseph's Clinical Research - Anaheim
- eStudySite - Chula Vista - PPDS - Chula Vista
- Central Valley Research LLC - Fresno
- Marvel Clinical Research - Huntington Beach
- eStudySite - La Mesa - PPDS - La Mesa
- Omnibus Clinical Research - La Palma
- Alliance Research LLC - Long Beach
- Long Beach Clinical Trials - Long Beach
- Central Valley Research, LLC - Modesto
Other
- University Multiprofile Hospital for Active Treatment - Pleven
- University Multiprofile Hospital for Active Treatment - Plovdiv
- University Multiprofile Hospital for Active Treatment - Rousse
- "University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N. I. Pirogov"", Clinic of Purulent-Septic Surgery-"N.I. Pirogov"" - Sofia
Florida
- Gonzalez MD and Aswad MD Health Services - Coral Gables
- L&C Professional Medical Research Institute - Miami
Nevada
- eStudySite - Las Vegas - PPDS - Las Vegas
- Excel Clinical Research - Las Vegas
Montana
- Mercury Street Medical Group - Butte
New Jersey
- South Jersey Infectious Disease - Somers Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 679 participants |
| Start Date | 2018-02-19 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03137173
The ClinicalTrials.gov registry entry for NCT03137173 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 679 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Bacterial Skin and Skin Structure Infections appearing as the primary indexed condition, and to 2 interventions - of which ceftobiprole medocaril is the first listed.
NCT03137173 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT03137173 about?
NCT03137173 is a clinical study titled "Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections". This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSS...
What is the current status of trial NCT03137173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 679 participants. The study started on 2018-02-19. Estimated completion is 2019-04-22.
What conditions does trial NCT03137173 study?
This clinical trial studies the following conditions: Acute Bacterial Skin and Skin Structure Infections.
What interventions are being tested in trial NCT03137173?
The interventions under investigation include: ceftobiprole medocaril (DRUG), vancomycin+aztreonam (DRUG).
Who is sponsoring clinical trial NCT03137173?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03137173 being conducted?
This trial has 20 study locations across California, Florida, Montana, Nevada, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Bacterial Skin and Skin Structure Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.